Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-02. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Disagreements arose, because the brigand wanted to assault Platì and take revenge on the local liberals, unlike Borjes, who eventually gave in. The unsuccessful assault took place on September 17. The brigands and legitimists were repelled by the National Guards and a regular army unit. This failure soon ended their collaboration. On October 20 Borjes traveled to Basilicata to join his forces with those of Carmine Crocco. They achieved successes, but not the final objective, as the brigand leader refused to turn his men into a regular army. Noting the failure of the plan, the Catalan general attempted to travel to Rome to report to the Bourbon ruler. He was captured in Tagliacozzo and shot on 8 December 1861. Borjes' failure did not end brigandage, which continued with greater virulence. For this reason, the first Minghetti government promulgated the Pica law on 15 August 1863. It was a regulation that suspended constitutional guarantees for the southern provinces and imposed a state of siege. It delivered brigands to military tribunals, without appeal or defense. In Calabria the law was applied in Citeriore and Calabria Ulteriore Seconda, while the Reggio area, as was the area around Naples and part of Apulia were exempted. The Pica law remained in force until 31 December 1865, and contributed to eradicating banditry, albeit with repressive methods and without resolving the southern territories' social and economic problems. An underlying issue was latifundium (estates), which were in the hands of a few economic and political elites.
After they see Randy wearing one of his daughter's crop-tops (which he has donned in order to embarrass her into dressing more conservatively), they invite him to a semaglutide-sharing party. Randy begins taking the drug himself, believing it to be a party drug that leaves him with neither a hangover nor an appetite, though this leaves his wife Sharon feeling self-conscious about her weight. She begins taking Lizzo, but it causes her to defecate from her ears. The doctor tells her she has developed "diabeartes", a form of diabetes that afflicts the ears. This means she now qualifies for semaglutide, which he prescribes her. After the homemade semaglutide appears to be successful in curbing Cartman's appetite, Kyle decides to produce more in order to benefit people who cannot afford it. However, news of this draws the ire of a sugar industry cartel consisting of mascots of breakfast cereals and sugary snacks. In addition, when a government crackdown in response to semaglutide abuse leaves the mothers without their supply, they and Randy begin robbing pharmacies, and then Kyle and his friends. The boys' supply is then destroyed when the sugar mascots, posing as "body positivity activists", attack the Indian factory, murdering the workers and burning the building to the ground. Kyle finds and purchases a truckload of semaglutide powder from another supplier in North Carolina, but it is carjacked by Randy and the mothers. However, Randy realizes that what the mothers are doing is wrong and steals the truck without them.
== Extraction and representation == On an industrial scale, diallyl disulfide is produced from sodium disulfide and allyl bromide or allyl chloride at temperatures of 40–60 °C in an inert gas atmosphere; sodium disulfide is generated in situ by reacting sodium sulfide with sulfur. The reaction is exothermic and its theoretical efficiency of 88% has been achieved in practice.
Sources: en.wikipedia.org
=== Pharmacodynamics === Penbutolol is able to bind to both beta-1 adrenergic receptors and beta-2 adrenergic receptors (the two subtypes), thus making it a non-selective β blocker. Penbutolol is a sympathomimetic drug with properties allowing it to act as a partial agonist at β adrenergic receptors. Blocking β adrenergic receptors decreases the heart rate and cardiac output to lower arterial blood pressure. β blockers also decrease renin levels, which ultimately results in less water being reabsorbed by the kidneys and therefore a lower blood volume and blood pressure. Penbutolol acts on the β1 adrenergic receptors in both the heart and the kidney. When β1 receptors are activated by a catecholamine, they stimulate a coupled G protein which activates adenylyl to convert adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). The increase in cAMP ultimately alters the movement of calcium ions in heart muscle and increases heart rate. Penbutolol blocks this and decreases heart rate, which lowers blood pressure. The ability of penbutolol to act as a partial agonist proves useful in the prevention of bradycardia as a result of decreasing the heart rate excessively. Penbutolol binding β1 adrenergic receptors also alters kidney functions. Under normal physiological conditions, the enzyme renin converts angiotensinogen to angiotensin I, which will then be converted to angiotensin II.
=== Semiconductors === Cadmium is an element in some semiconductor materials. Cadmium sulfide, cadmium selenide, and cadmium telluride are used in some photodetectors and solar cells. HgCdTe detectors are sensitive to mid-infrared light and used in some motion detectors.
== History == Humans have inhabited the atoll since about 1,000 B.C. The islands were first settled by Austronesian islanders. The first European colonizers to Enewetak, Spanish explorer Álvaro de Saavedra Cerón, arrived on 10 October 1529. He called the island "Los Jardines" (The Gardens). In 1794, sailors aboard the British merchant sloop Walpole called the islands "Brown's Range" (thus, the Japanese name "Brown Atoll"). It was visited by about a dozen ships before the establishment of the German colony of the Marshall Islands in 1885.
== Major branches == Modern neuroscience education and research activities can be very roughly categorized into the following major branches, based on the subject and scale of the system in examination as well as distinct experimental or curricular approaches. Individual neuroscientists, however, often work on questions that span several distinct subfields.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.